



31 JUL 2005

(43) International Publication Date
19 February 2004 (19.02.2004)


PCT

(10) International Publication Number
WO 2004/014955 A1

- (51) International Patent Classification⁷: C07K 16/42, 14/705, C12N 5/16, A61K 38/17, 38/08
- (21) International Application Number: PCT/EP2003/008365
- (22) International Filing Date: 28 July 2003 (28.07.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 02447150.0 31 July 2002 (31.07.2002) EP
- (71) Applicant (for all designated States except US): D. COLLEN RESEARCH FOUNDATION VZW [BE/BE]; Onderwijs en Navorsing Campus Gashuisberg K.U.Leuven, Herestraat 49, B-3000 Leuven (BE).
- (72) Inventors; and
- (73) Inventors/Applicants (for US only): GILLES, Jean-Guy, G. [BE/BE]; Avenue de l'Exposition 410, B-1090 Bruxelles (BE). SAINT-REMY, Jean-Marie, R. [BE/BE]; Rue du Lambais 79, B-1390 Grez-Doiceau (BE).
- JACQUEMIN, Marc, G. [BE/BE]; Rue Morimont 45, B-5330 Sart-Bernard (BE).
- (74) Agents: BIRD, William, E. et al.; Bird Goën & Co, Klein Dalenstraat 42 A, B-3020 Winksele (BE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:
— of inventorship (Rule 4.17(iv)) for US only

(Continued on next page)

(54) Title: ANTI-IDIOTYPIC ANTIBODIES AGAINST FACTOR VIII INHIBITOR AND USES THEREOF



(57) Abstract: The present invention discloses anti-idiotypic antibodies and fragments thereof against inhibitory Factor VIII antibodies, said inhibitory antibodies having an affinity for the C2 domain of Factor VIII. The anti-idiotypic antibodies of the present invention are able to completely neutralise in vitro and in an in vivo mouse model the inhibitory activity of FVIII inhibitors. The anti idiotypic antibodies of the present invention can be applied for the prevention, treatment or reduction of bleeding disorders of hemophilia patients with inhibitory antibody against the C2 domain of Factor VIII.

BEST AVAILABLE COPY

WO 2004/014955 A1